Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
27 sept. 2024 09h35 HE
|
Regeneron Pharmaceuticals, Inc.
Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following...
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
27 sept. 2024 07h00 HE
|
Regeneron Pharmaceuticals, Inc.
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved...
Vaping Expected to Increase COPD Health and Economic Burden by 2050
10 sept. 2024 08h00 HE
|
ResMed Inc.
Vaping Expected to Increase COPD Health and Economic Burden by 2050
New ResMed-supported research presented at ERS 2024
Wellinks Recognized as Quarterfinalist for the Digital Health Hub Foundation: Digital Health Awards
04 sept. 2024 11h00 HE
|
Wellinks Inc.
NEW HAVEN, Conn., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Wellinks, is thrilled to announce its selection as a quarterfinalist for the prestigious 2024 Digital Health Hub Foundation: Digital Health...
Innovative New COPD Maintenance Treatment Now Available Through DirectRx Specialty Pharmacy
28 août 2024 11h51 HE
|
DirectRx Pharmacy
DirectRx selected for exclusive distribution network for the newest and first-in-class COPD medication, Ohtuvayre by Verona Pharma
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases
26 août 2024 01h00 HE
|
Regeneron Pharmaceuticals, Inc.
20 abstracts, including 4 oral presentations, offer new treatment insights for chronic obstructive pulmonary disease (COPD), asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) Data from...
Wellinks Integrates Virtual Pulmonary Rehabilitation Program at UMass Memorial Health for Massachusetts Residents Living with COPD
08 août 2024 11h17 HE
|
Wellinks Inc.
NEW HAVEN, Conn., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Wellinks, a digital healthcare company offering comprehensive value-based solutions for Chronic Obstructive Pulmonary Disease (COPD) management,...
Acute Respiratory Distress Syndrome Analysis Report 2024: A $2.36 Billion Market by 2032 from $1.23 Billion in 2023
18 juil. 2024 06h27 HE
|
Research and Markets
Dublin, July 18, 2024 (GLOBE NEWSWIRE) -- The "Acute Respiratory Distress Syndrome Market Report by Type, End User, Regions and Company Analysis 2024-2032" report has been added to ...
RS BioTherapeutics Announces Research Collaboration with University of Colorado School of Medicine
08 juil. 2024 10h00 HE
|
RS BioTherapeutics
CUMBERLAND, Md., July 08, 2024 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from deadly lung diseases...
Pneumagen Highlights Broad-Spectrum Antiviral Activity of First-in-Class Intranasal Drug Neumifil in New Publication
03 juil. 2024 04h00 HE
|
Pneumagen Ltd
Pneumagen has previously reported positive results from both Phase 1 and a clinical proof of concept Phase 2 Human Influenza Challenge study demonstrating the potential of NeumifilNew preclinical...